Christopher Woods, MD PhD is a cardiac electrophysiologist with a particular focus on both atrial fibrillation and complex ventricular tachycardia. He serves as Chief Medical Director of Clinical Trial Operations for the Sutter Health Research Enterprise, and Medical Director of the Atrial Fibrillation and Complex Arrhythmia Center (AFCAC) at Sutter Health’s Mills-Peninsula Medical Center and California Pacific Medical Center. Dr. Woods’ research focuses on translational cardiovascular diseases. He investigates novel therapies for supraventricular tachycardia, atrial fibrillation, and ventricular tachycardia, as well as stroke prevention. These include investigator-initiated and industry-supported clinical trials in the focus areas described above. Dr. Woods received an M.D. and Ph.D. from the University of California at Los Angeles through the NIH Medical Scientist Training Program. He completed residency training in internal medicine at Stanford University as part of the clinical investigator pathway, fellowship and chief fellowship in cardiology also at Stanford, and clinical cardiac electrophysiology fellowship at the University of California at San Francisco.
The diagnosis, risk stratification, and treatment of cancer have become increasingly personalized. Clinicians utilize novel testing technologies to select targeted therapeutics based on predictive biomarkers. The advent of newer and less invasive approaches to diagnosis such as liquid biopsy is enabling clinicians to better tailor treatment plans for their patients. Novel immunotherapy agents used alone or in combination with other agents may further optimize outcomes for patients with advanced disease. This session will explore the unique challenges that community-based clinicians face in their practice.